Search results
Results From The WOW.Com Content Network
Gemcitabine is in the nucleoside analog family of medication. [3] It works by blocking the creation of new DNA, which results in cell death. [3] Gemcitabine was patented in 1983 and was approved for medical use in 1995. [7] Generic versions were introduced in Europe in 2009 and in the US in 2010. [8] [9] It is on the WHO Model List of Essential ...
GVD is a chemotherapy regimen, used for salvage treatment of relapsed or refractory Hodgkin disease, including those patients who relapse after stem cell transplantation. [1]
Radiolab is a radio program broadcast on public radio stations in the United States and through a podcast available internationally, both produced by WNYC.Hosted by Latif Nasser and Lulu Miller, each episode delves into scientific and philosophical topics through stories, interviews, and thought experiments.
There is a large family of nucleoside analogue reverse transcriptase inhibitors, because DNA production by reverse transcriptase is very different from normal human DNA replication, so it is possible to design nucleoside analogues that are preferentially incorporated by the former. Some nucleoside analogues, however, can function both as NRTIs ...
A hypomethylating agent (or demethylating agent [1]) is a drug that inhibits DNA methylation: the modification of DNA nucleotides by addition of a methyl group.Because DNA methylation affects cellular function through successive generations of cells without changing the underlying DNA sequence, treatment with a hypomethylating agent is considered a type of epigenetic therapy.
Azacitidine is a chemical analogue of the nucleoside cytidine, which is present in DNA and RNA.It is thought to have antineoplastic activity via two mechanisms – at low doses, by inhibiting of DNA methyltransferase, causing hypomethylation of DNA, [16] and at high doses, by its direct cytotoxicity to abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA ...
Gene knock-in originated as a slight modification of the original knockout technique developed by Martin Evans, Oliver Smithies, and Mario Capecchi.Traditionally, knock-in techniques have relied on homologous recombination to drive targeted gene replacement, although other methods using a transposon-mediated system to insert the target gene have been developed. [3]
8 March 2007 () Joan Rivers and Julian McMahon: 4: 4: 15 March 2007 () Jenny Eclair and Louis Walsh: 5: 5: 22 March 2007 () Ioan Gruffudd, Jessie Wallace and Scooch: 6: 6: 29 March 2007 () David Tennant, Jo Brand and The Proclaimers: 7: 7: 12 April 2007 () Julia Sawalha, Liz Smith and Alan Bates: 8: 8